Please try another search
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Emma Guttman-Yassky | - | - | Member of Clinical & Scientific Advisory Board |
Alexa Boer Kimball | - | - | Member of Clinical & Scientific Advisory Board |
Somasundaram Subramaniam | 70 | 2018 | Independent Director |
Onaiza Cadoret-Manier | 59 | 2023 | Independent Director |
Raju S. Mohan | 67 | 2018 | Founder, CEO, President & Director |
James G. Krueger | - | - | Member of Clinical & Scientific Advisory Board |
William J. Sandborn | 61 | 2022 | Chairman of Clinical Advisory Board |
Bruce E. Sands | - | - | Member of Clinical & Scientific Advisory Board |
William R. White | 51 | 2021 | Independent Director |
Luisa Salter-Cid | 60 | 2021 | Member of Advisory Board |
Allison J. Hulme | 61 | 2023 | Independent Director |
Sheila K. Gujrathi | 54 | 2021 | Executive Chairperson |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review